Cargando…
Hypersomatotropism in 3 Cats without Concurrent Diabetes Mellitus
Autores principales: | Fletcher, J.M., Scudder, C.J., Kiupel, M., Pipe‐Martin, H.N., Kenny, P.J., Mantis, P., Fenn, J., Smith, K., Blair, R.V., Granger, L.A., Niessen, S.J.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089606/ https://www.ncbi.nlm.nih.gov/pubmed/27255700 http://dx.doi.org/10.1111/jvim.14360 |
Ejemplares similares
-
Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015) -
Efficacy of hypophysectomy for the treatment of hypersomatotropism‐induced diabetes mellitus in 68 cats
por: Fenn, Joe, et al.
Publicado: (2021) -
Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
por: Gostelow, R., et al.
Publicado: (2017) -
Serum N‐Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism
por: Keyte, S.V., et al.
Publicado: (2016) -
Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats
por: van Bokhorst, Kirsten L., et al.
Publicado: (2021)